Dermapharm Holding SE
DMP
Rank in Stocks
#5706
Dermapharm Holding SE, alongside its group companies, specializes in the... Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Share Price
$43.04
Last synced: 2026-11-09
Market Cap
$2.13B
Change (1 day)
1.60%
Change (1 year)
9.75%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Dermapharm Holding SE (DMP)
Category
Healthcare
Operating Margin for Dermapharm Holding SE (DMP)
Operating Margin as of November 2026 TTM: 22.03%
According to Dermapharm Holding SE's latest financial reports, its current operating margin (TTM) is 22.03%. At the end of 2025 the company had an operating margin of 19.03%.
Operating Margin history for Dermapharm Holding SE from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 22.03% | 15.76% |
| 2025 | 19.03% | 3.59% |
| 2024 | 18.37% | 14.03% |
| 2023 | 16.11% | -32.25% |
| 2022 | 23.78% | -24.87% |
| 2021 | 31.65% | 83.58% |
| 2020 | 17.24% | 1.11% |
| 2019 | 17.05% | -9.21% |
| 2018 | 18.78% | -4.77% |
| 2017 | 19.72% | 0.97% |
| 2016 | 19.53% | 23.69% |
| 2015 | 15.79% | 42.90% |
| 2014 | 11.05% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -99.12% |
DE
|
|
| 19.68% | -99.11% |
DE
|
|
| 13.26% | -99.40% |
JP
|
|
| 17.08% | -99.22% |
CH
|
|
| 14.92% | -99.32% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Dermapharm Holding SE's operating margin
What is Dermapharm Holding SE's operating margin?
Dermapharm Holding SE's operating margin is 22.03%, as of Nov 2026.
What was Dermapharm Holding SE's operating margin in 2025?
In 2025, Dermapharm Holding SE's operating margin was 19.03%, compared with 18.37% in 2024.
How has Dermapharm Holding SE's operating margin changed since 2020?
From 2020 to 2025, Dermapharm Holding SE's operating margin was highest in 2021 (31.65%) and lowest in 2023 (16.11%).
How does Dermapharm Holding SE's operating margin compare with similar companies?
Dermapharm Holding SE's operating margin (22.03%) is higher than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.